Novogene Acquires China Rights to Urine-based DNA Collection Device

Novogene, a Beijing genomics services company, partnered with San Diego's Trovagene to validate and use Tovagene's NextCollect™ in China. NextCollect is a proprietary urine collection and nucleic acid preservation device that stabilizes up to 200 ml of a urine sample for two weeks at room temperature. According to Trovagene, the device increases the quality and quantity of DNA that can be isolated from urine. Presently, NextCollect is a research-only device, but Novogene intends to develop clinical applications. More details.... Stock Symbol: (NSDQ: TROV) Share this with colleagues: // //